Kobenhavns Universitet Patent applications |
Patent application number | Title | Published |
20140235576 | PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS IGLUR ANTAGONISTS - The present invention relates to compounds of Formula (I), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are iGluR receptor inhibitors, and hence are useful in the treatment of psychiatric diseases or neurological disorders or a disease or disorder associated with abnormal activities of iGluR receptors. | 08-21-2014 |
20140234294 | Fibroblast Growth Factor Receptor-Derived Peptides Binding to NCAM - The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role. | 08-21-2014 |
20140120105 | THERAPEUTIC TARGETING OF FICOLIN-3 - The present Invention relates to novel antibodies against Ficolin-3, which antibodies inhibit complement activation. The invention further relates to the use of anti-Ficolin-3 antibodies in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to nucleic acid molecules encoding such antibodies, vectors and host cells used in the production of the antibodies. | 05-01-2014 |
20140030421 | PROCESS FOR THE MANUFACTURE OF A PRODUCT FROM A PLANT MATERIAL - The present invention relates to a process for the manufacture of a product from a plant material including the steps of providing a disrupted plant material including <10% (w/w) starch and <10% (w/w) oil/lipids; adjusting the pH of the disrupted plant material to a value of pH 3.5 or below to pro-vide an acidic suspension; heating the acidic suspension to a temperature in the range of about 50° C. to about 80° C.; isolating the product from the heat-ed, acidic suspension. The product may be a protein product or a non-protein product. In particular, the process of the invention provides a protein product with reduced contents of non-protein components of negative nutri-tional value. | 01-30-2014 |
20130203113 | METHOD OF STABILIZING mRNA - There is provided a method to increase the production of a desired protein in a microorganism by introduction of slowly translated codons in the encoding DNA gene sequence capable of slowing down the translation speed of the ribosomes moving along the mRNA, whereby the ribosomes protect the mRNA from being enzymatically degraded. This increases the stability of the mRNA transcript and thus results in an increased production of the desired protein. Moreover, there is provided a method of decreasing the half-life of a mRNA transcript from a gene encoding a peptide. | 08-08-2013 |
20120128770 | TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE - The present invention relates to 1 or 2 C16-C18 acyl glycerol based compounds which are capable of activating G-protein coupled receptor 119 and thereby stimulate GLP-1 release. Compounds of the present invention are useful in the prophylaxis and/or treatment of metabolic disorders and complications thereof, such as, type 2 diabetes mellitus (T2DM), obesity, insulin resistance, and cardiovascular disease. | 05-24-2012 |
20120058223 | COLD-ACTIVE BETA-GALACTOSIDASE, A METHOD OF PRODUCING SAME AND USE OF SUCH ENZYME - A novel cold-active beta-galactosidase is enzyme specific for lactose. The enzyme is thus useful in e.g. the food industry for catalyzing at low temperatures the hydrolysis of lactose disaccharide into its constituent monosaccharides, glucose and galactose. A method produces the cold-active beta-galactosidase by recombinant DNA technology. | 03-08-2012 |
20120058087 | DIAGNOSIS OF ENDOMETRITIS - The present invention relates to methods for diagnosing and treatment of a dormant infection of at least one pathogen. The invention further relates to a composition comprising an anti-dormancy factor as well as to said composition for use in a method of diagnosis or treatment and also to a method for manufacturing said composition. The invention further relates to a kit of parts comprising, inter alia, said composition. The invention also relates to a method for activating a dormant infection. | 03-08-2012 |
20120021937 | DETECTION OF CARCINOMA IN SITU IN SEMEN SPECIMENS - The present invention provides a method for the detection of testicular cancer and/or precursors hereof by screening a sample for the presence of at least two markers in the same cell, wherein the sample is a semen sample and/or an ejaculate from a male human being. | 01-26-2012 |
20120003741 | HEPATITIS C VIRUS EXPRESSING REPORTER TAGGED NS5A PROTEIN - The present inventors developed hepatitis C reporter viruses containing Core through NS2 of prototype isolates of all major HCV genotypes and the remaining genes of isolate JFH1, by insertion of reporter genes in domain III of HCV NS5A. The inventors have identified a deletion upstream of the inserted reporter gene sequence, which conferred favourable growth kinetics in Huh7.5 cells to these viruses. These reporter viruses can be used for high throughput analysis of drug and vaccine candidates as well as patient samples. Drugs could be evaluated for their potential to prevent infection or cure infected cells. The neutralizing capacity of antibodies induced by vaccine candidates could be evaluated in order to define successful vaccination strategies. Broadly neutralizing antibodies could be identified testing engineered antibodies and antibodies derived from serum of HCV infected individuals; thus this technique could contribute to the development of immunotherapy. The developed systems could aid individualized treatment of HCV infected: Patient isolates could be tested for resistance to drugs by introduction of genome regions involved in drug resistance in the developed constructs and subsequent treatment with the drug of interest. The present inventors also developed JFH1-based intergenotypic recombinants with genotype specific homotypic 5UTR, or heterotypic 5′UTR (either of genotype 1a (strain H77) or of genotype 3a (strain S52)). The present inventors additionally developed J6/JFH1 recombinants with the 5′UTR of genotypes 1-6. These recombinants with different 5UTRs are a useful to study the function of the 5′UTR in a genotype specific manner. | 01-05-2012 |
20110171090 | METHOD AND DEVICE FOR CLEANING AIR - A method and device for cleaning air. The air to be cleaned is directed as a continuous flow in succession through a) a first zone wherein the air is treated with ozone and possibly also water, ammonia or other aerosol growth promoters; b) a second zone wherein the air is subjected to ultraviolet light; c) a third zone wherein the air is maintained for a sufficient time to allow aerosol growth; d) a fourth zone where particles in the air are given an electrical charge; e) a fifth zone wherein the air is passed through an electrostatic filter; and f) a sixth zone wherein the air flows over a catalyst to break down residual ozone. The air in confined spaces including indoor rooms, public vehicles with limited access to fresh air is subjected to a low energy consuming universal broad-spectrum removal of the various types of indoor air pollution including toxic gases, organic compounds, microorganisms and liquid and solid particles being hazardous to health and detrimental to quality of life. | 07-14-2011 |
20110111023 | PREVENTION OF TYPE 1 DIABETES BY ADMINISTRATION OF GLIADIN - The invention herein is related to intranasal or other mucosal administration of gliadin, or parts thereof, to prevent the development of type 1 diabetes. This environmental antigen, which may have etiological role in the development of diabetes in genetically predisposed individuals, has been successfully applied in the prevention of disease. | 05-12-2011 |
20100296963 | CRYSTAL STRUCTURE OF A PLASMA MEMBRANE PROTON PUMP - The present invention relates to a crystal structure of a plasma membrane proton pump type ATPase. The invention further describes method for identification of modulators of ATPases as well as uses of such modulators. Based on the provided three dimensional structure of the ATPase, various method, such as computer implemented methods may be used for identification of modulators, such putative modulators may be further analysed using in vitro and in vivo experiments to confirm there functionality. Several modulator interaction regions are described as target of regulation by ATPase modulators. | 11-25-2010 |
20100139759 | OPTICAL DEVICE - The present invention relates to an optical device and to a method of fabricating the same. In embodiments, the invention relates to a photovoltaic device or solar cell. The optical device comprises a first electrode and a second electrode and an active element disposed between the first and second electrodes. The active element comprising a plurality of semiconducting structures extending in a lengthwise direction from the first electrode and being in contact with the first and second electrodes; the active element comprises an np-junction. For the semiconducting structures, at least a part of the structures is of a general plate or flake shape. In embodiments, the semiconducting structures have at least one characteristic dimension in the nanometer range. | 06-10-2010 |
20100034825 | GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES - The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis. | 02-11-2010 |
20090307788 | RIBOZYME MEDIATED STABILIZATION OF POLYNUCLEOTIDES - The present invention relates to the production of novel, recombinant polynucleotides comprising the GIR1 ribozyme, or a variant thereof, vectors comprising such polynucleotides and recombinant host cells comprising such polynucleotides and/or such vectors. The invention furthermore relates to the use of said polynucleotides in the treatment of an individual suffering from a disease associated with or caused by instability of a transcript of said second subsequence such as cancer, cachexia, α-Thallasemia or leukaemia. | 12-10-2009 |
20090029372 | ADAM12 AS A BIOMARKER FOR BLADDER CANCER - The present inventors have shown that the gene and protein expression profiles of ADAM8, ADAM10 and ADAM12 in different grades and stages of bladder cancer. | 01-29-2009 |